News
Eli Lilly CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in ...
The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
15h
TipRanks on MSNEli Lilly’s Orforglipron Study: A New Hope for Obesity Treatment?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...
Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from ...
18h
Global News - Inquirer.net on MSNWill China’s home-grown obesity drugs reshape global weight loss market?
July, video editor Meng Meng, 38, has been injecting herself with a weekly weight loss drug, hoping it will finally help her ...
The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...
The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity ...
More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results